16:48:59 EST Tue 03 Nov 2026
Enter Symbol
or Name
USA
CA



USANA Health Sciences Reports Third Quarter 2026 Results

2026-11-03 16:05 ET - News Release

Hiya Active Monthly Subscribers Increase 18% Sequentially; Core Nutritional Operating Margin Expands; Company Generates $36 Million in Year-to-Date Free Cash Flow


SALT LAKE CITY -- (Business Wire)

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 3, 2026.

Key Financial Results

Third Quarter 2026 vs. Third Quarter 2025

  • Net sales of $206 million versus $214 million.
  • Net loss of $(5.6) million versus $(6.5) million.
  • Diluted EPS of $(0.30) as compared with $(0.36).
  • Adjusted diluted EPS(1) of $(0.11) as compared with $(0.15).
  • Adjusted EBITDA(2) of $12.1 million versus $13.8 million.
  • Core Nutritional Active Customers of 356,000 versus 388,000.
  • Hiya Active Monthly Subscribers of 195,500 versus 193,400.
  • Company updates fiscal 2026 guidance to net sales approaching $900 million and Adjusted EBITDA(2) of $77 million.

Q3 2026 Consolidated Performance

 

Q3 2026

Year-Over-Year

Sequentially

Net Sales

$206 million

-4% (+$4 million or +2% FX impact)

-8%

Net Loss*

$(5.6) million

N/A

N/A

Diluted EPS

$(0.30)

N/A

N/A

Adjusted Diluted EPS(1)

$(0.11)

N/A

N/A

Adjusted EBITDA(2)

$12.1 million

-13%

-44%

*Income tax expense of $6 million added to a pretax loss of $(1) million for Q3 2026.

Net Loss, EPS and EBITDA figures represent amounts attributable to USANA and exclude the noncontrolling interest of 21.2% in Hiya.

“As we continue our transformation to an omnichannel health and wellness company, our third quarter results were mixed, with meaningful improvement in some areas and results that fell short of our expectations in others,” said Kevin Guest, Chairman and Chief Executive Officer. “We are investing across each of our businesses to strengthen their long-term competitive position and made clear progress in key areas. At Hiya, as customer acquisition began responding positively during the quarter, we increased marketing spend to build on that traction, which pressured margins but generated an 18% sequential increase in active subscribers and returned the segment to year-over-year net sales growth. Additionally, our Core Nutritional business expanded its operating margin from a year ago on a leaner cost structure despite lower net sales. While we have more work to do in growing Core Nutritional active customers and net sales at Rise Wellness, we believe we have the right strategies in place.

“In Core Nutritional, rebuilding our active customer base is our top priority and our single largest growth lever. For example, active customers in the Southeast Asia Pacific region grew 3% sequentially in the third quarter, demonstrating what works when our initiatives and execution align. We are evolving our Brand Partner incentive plan to more directly reward growth in active customers, investing in digital marketing to build awareness of the USANA brand, and advancing product innovation that we plan to begin introducing in 2027.

“At Hiya, our investment in customer acquisition is producing encouraging early returns. Notably, Hiya added approximately 29,500 net active monthly subscribers sequentially, customer acquisition costs declined noticeably from the first half of the year and net sales through Target and Amazon more than doubled from the second quarter. Because Hiya is predominantly a subscription business today, the subscribers we add support results in future quarters. Additionally, Hiya continues to make progress in broadening its reach beyond direct-to-consumer, and we look forward to providing updates in early 2027.

“At Rise Wellness, we are building on a strengthening retail foundation and working towards improved margins. As planned, we launched Protein Pop Balance nationally at Target and online in September, and Target sales grew strongly from the second quarter. Our focus is converting this progress into consistent, profitable growth.”

Q3 2026 Segment Results

Core Nutritional

Core Nutritional

 

Q3 2026

Year-Over-Year

Year-Over-Year
(Constant Currency)

Sequentially

Net Sales

$171 million

-3%

-6%

-11%

Active Customers

356,000

-8%

N/A

-7%

Asia Pacific Region

 

Q3 2026

Year-Over-Year

Year-Over-Year
(Constant Currency)

Sequentially

Net Sales

$138 million

-1%

-4%

-12%

Active Customers

283,000

-8%

N/A

-8%

Asia Pacific Sub-Regions

 

 

Q3 2026

Year-Over-Year

Year-Over-Year
(Constant Currency)

Sequentially

Greater China

Net Sales

$94 million

+1%

-3%

-18%

Active

192,000

-9%

N/A

-11%

Customers

North Asia

Net Sales

$14 million

-20%

-18%

+3%

Active

30,000

-19%

N/A

-6%

Customers

Southeast Asia Pacific

Net Sales

$30 million

+2%

+2%

+4%

Active

61,000

Flat

N/A

+3%

Customers

Americas and Europe Region

 

Q3 2026

Year-Over-Year

Year-Over-Year
(Constant Currency)

Sequentially

Net Sales

$33 million

-11%

-12%

-5%

Active Customers

73,000

-9%

N/A

-5%

Hiya Health

 

Q3 2026

Year-Over-Year

Sequentially

Net Sales

$32 million

+2%

+12%

Active Monthly Subscribers

195,500

+1%

+18%

Rise Wellness

 

Q3 2026

Year-Over-Year

Sequentially

Net Sales

$4 million

-45%

+7%

Balance Sheet

The Company ended the quarter with $179 million in cash and cash equivalents and zero debt. As of October 3, 2026, inventory totaled $93 million, a decrease of approximately $14 million, or 13%, compared to balances at year-end 2025.

The Company did not repurchase any shares during the quarter and has approximately $34 million remaining under the current share repurchase authorization as of the end of the third quarter.

Fiscal Year 2026 Outlook

The Company is updating its outlook for fiscal year 2026, as follows:

Fiscal Year 2026 Outlook

 

Updated Estimate

Previous Estimate

Core Nutritional business net sales

$740 million*

$750 million

Hiya net sales

$130 million

$125 million

Rise Wellness net sales

$30 million

$35 million

Consolidated net sales

Approaching $900 million

$910 million

 

 

 

Net (loss) earnings

$(16) million

$(11) million

Diluted EPS

$(0.90)

$(0.61)

Adjusted diluted EPS(1)

$0.55

$0.76

Adjusted EBITDA(2)

$77 million

$80.5 million†

*

Reflects an expected favorable currency exchange rate impact of approximately $20 million, or 2% of net sales and one less week of operations compared to fiscal year 2025, which was a 53-week year.

†

As corrected; previously published as $87 million on August 4, 2026. See “Correction of Previously Reported Adjusted EBITDA Attributable to USANA” below.

“Consolidated net sales declined 4% in the third quarter, as growth at Hiya was more than offset by lower sales in Core Nutritional and Rise,” said Doug Hekking, Chief Financial Officer. “We made progress on improving profitability in our Core Nutritional segment during the quarter, while we chose to increase investment at Hiya to accelerate subscriber growth, which weighed on margins in the quarter but produced strong growth in active monthly subscribers.

“We generated $8 million of free cash flow(3) in the quarter and $36 million year-to-date, reduced inventory 13% from year-end, and ended the period with $179 million in cash and no debt. That financial strength gives us the flexibility to continue investing in the initiatives we expect to drive future growth across our businesses, including our omnichannel strategy, while maintaining financial discipline.

“We are updating our fiscal 2026 outlook to consolidated net sales approaching $900 million and Adjusted EBITDA of $77 million. Compared with our prior outlook, as corrected, the change reflects lower expectations for Rise Wellness and our deliberate decision to invest resources at Hiya to drive increased active monthly subscribers, partially offset by stronger profitability in Core Nutritional. We expect continued sequential progress from Hiya during the fourth quarter on both net sales and Adjusted EBITDA. While these investments constrain near-term results, we believe they set the stage for renewed growth across our businesses, and we plan to enter 2027 with a strong balance sheet and clear priorities to deliver it.”

Correction of Previously Reported Adjusted EBITDA Attributable to USANA

In preparing its third quarter results, the Company identified an omission in its second quarter 2026 reconciliation of net (loss) earnings to Adjusted EBITDA attributable to USANA. The $29.1 million Hiya goodwill impairment was added back in full, rather than net of the $6.2 million share attributable to the noncontrolling interest. This correction affects Adjusted EBITDA attributable to USANA, a non-GAAP measure, and had no effect on the Company’s reported GAAP results. Corrected amounts are as follows:

Adjusted EBITDA attributable to USANA

 

As previously reported

 

Correction

 

As corrected

Second quarter 2026

 

$ 27.8

 

$ (6.2)

 

$ 21.7

Fiscal 2026 outlook (August 4, 2026)

 

86.7

 

(6.2)

 

80.5

$ in millions

Sequential comparisons and the previous outlook presented in this release reflect the corrected amounts. Amounts may not sum due to rounding.

____________________

(1)

Adjusted Diluted (Loss) Earnings Per Share is a non-GAAP financial measure. The Company excludes cost realignment expenses, impairment expense, gain on sale of assets, and acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition-related intangible assets in calculating Adjusted Diluted (Loss) Earnings Per Share. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted Loss Per Share (GAAP) to Adjusted Diluted Loss Per Share (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.

(2)

Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.

(3)

Free cash flow is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net Cash Provided by (Used in) Operating Activities (GAAP) to Free Cash Flow (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.

Non-GAAP Financial Measures

This press release contains the non-GAAP financial measures Adjusted EBITDA, Adjusted Diluted EPS and free cash flow. Adjusted EBITDA is a non-GAAP financial measure of (loss) earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net (loss) earnings. Adjusted Diluted EPS is a non-GAAP financial measure of diluted (loss) earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

Adjusted EBITDA (non-GAAP) is net (loss) earnings (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization (including right-of-use asset reduction), non-cash share-based compensation, transaction-related expenses and integration costs for the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest related to Hiya.

Adjusted diluted (loss) earnings per share (non-GAAP) is diluted (loss) earnings per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses and integration costs related to the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets.

Free cash flow (non-GAAP) is net cash provided by (used in) operating activities (its most directly comparable GAAP financial measure) less purchases of property and equipment. Management believes free cash flow is a useful measure of the cash the business generates, after investing in property and equipment, that is available for strategic investments, share repurchases and other uses.

Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), Adjusted diluted (loss) earnings per share (non-GAAP), and free cash flow (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”) and investors should not directly compare with or infer a relationship from any of the Company’s operating results presented in accordance with GAAP to Adjusted EBITDA, Adjusted diluted (loss) earnings per share and free cash flow. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for, financial information presented in accordance with GAAP.

Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (non-GAAP)
(in thousands)

 

 

 

Quarter ended

 

 

October 3,
2026

 

September 27,
2025

Net loss attributable to USANA (GAAP)

 

$

(5,556

)

 

$

(6,522

)

Net loss attributable to noncontrolling interest

 

 

(1,334

)

 

 

(140

)

Net loss

 

$

(6,890

)

 

$

(6,662

)

 

 

 

 

 

Adjustments:

 

 

 

 

Income taxes

 

$

6,086

 

 

$

8,456

 

Interest (income) expense, net

 

 

(607

)

 

 

(529

)

Depreciation and amortization

 

 

5,212

 

 

 

5,112

 

Amortization of intangible assets - Hiya

 

 

4,455

 

 

 

4,455

 

Earnings before interest, taxes, depreciation, and amortization (EBITDA)

 

$

8,256

 

 

$

10,832

 

 

 

 

 

 

Add EBITDA adjustments:

 

 

 

 

Non-cash share-based compensation

 

 

3,404

 

 

 

3,576

 

Transaction, integration and transition costs - Hiya

 

 

—

 

 

 

179

 

Adjusted EBITDA

 

 

11,660

 

 

 

14,587

 

Adjusted EBITDA attributable to noncontrolling interest

 

 

392

 

 

 

(803

)

Adjusted EBITDA attributable to USANA

 

$

12,052

 

 

$

13,784

 

Reconciliation of Diluted Loss Per Share (GAAP) to Adjusted Diluted Loss Per Share (non-GAAP)
(in thousands, except per share data)

 

 

 

Quarter ended

 

 

October 3,
2026

 

September 27,
2025

Net loss attributable to USANA (GAAP)

 

$

(5,556

)

 

$

(6,522

)

 

 

 

 

 

Loss per common share - Diluted

 

$

(0.30

)

 

$

(0.36

)

Weighted Average common shares outstanding - Diluted

 

 

18,498

 

 

 

18,293

 

 

 

 

 

 

Adjustment to net loss:

 

 

 

 

Transaction, integration and transition costs - Hiya

 

$

—

 

 

$

179

 

Amortization of intangible assets - Hiya

 

 

4,455

 

 

 

4,455

 

Adjustments to net loss attributable to noncontrolling interest

 

 

(942

)

 

 

(942

)

Adjusted net loss attributable to USANA

 

$

(2,043

)

 

$

(2,830

)

 

 

 

 

 

Adjusted loss per common share - Diluted

 

$

(0.11

)

 

$

(0.15

)

Weighted average common shares outstanding - Diluted

 

 

18,498

 

 

 

18,293

 

Reconciliation of Net Cash Provided by (Used in) Operating Activities (GAAP) to Free Cash Flow (non-GAAP)
(in thousands)

 

 

 

Quarter ended

 

Nine months ended

 

 

October 3,
2026

 

September 27,
2025

 

October 3,
2026

 

September 27,
2025

Net cash provided by (used in) operating activities (GAAP)

 

$

11,965

 

 

$

(1,961

)

 

$

45,043

 

 

$

25,739

 

Less: Purchases of property and equipment

 

 

(3,522

)

 

 

(3,198

)

 

 

(9,322

)

 

 

(11,028

)

Free cash flow (non-GAAP)

 

$

8,443

 

 

$

(5,159

)

 

$

35,721

 

 

$

14,711

 

Management Commentary Document and Conference Call

For further information on USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, November 4, 2026, at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a question-and-answer session.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “expect,” “enhance,” “drive,” “anticipate,” “intend,” “improve,” “promote,” “should,” “believe,” “continue,” “plan,” “goal,” “opportunity,” “estimate,” “predict,” “may,” “will,” “could,” and “would,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding commercial performance and growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company’s long-term growth; and the statements under the sub-heading “Fiscal Year 2026 Outlook.” Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to Hiya’s ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Hiya’s ability to perform in an expanding distribution channel and new international markets; risks related to Rise Wellness’ ability to execute its commercial plan and its dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts or such retailers discontinue purchasing and selling Rise Wellness products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict between the United States and Iran; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with our operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that Hiya and Rise Wellness disrupt the Company’s overall strategic plans and operations; the diversion of the attention of the management teams of USANA, Hiya, and Rise Wellness from ongoing business operations; the ability to retain key personnel of USANA, Hiya and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya’s business with USANA’s business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers across 25 global markets. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company, and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at www.hiyahealth.com. More information on Rise Wellness can be found at www.risebar.comand www.proteinpop.com.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)

 

 

Three months ended

 

October 3,
2026

 

September 27,
2025

Net sales

$

205,885

 

 

$

213,670

 

Cost of sales

 

48,717

 

 

 

48,815

 

Gross profit

 

157,168

 

 

 

164,855

 

Operating expenses:

 

 

 

Brand Partner incentives

 

71,890

 

 

 

77,684

 

Selling, general and administrative

 

86,726

 

 

 

85,947

 

Total operating expenses

 

158,616

 

 

 

163,631

 

(Loss) earnings from operations

 

(1,448

)

 

 

1,224

 

Other income (expense):

 

 

 

Interest income

 

645

 

 

 

578

 

Interest expense

 

(38

)

 

 

(49

)

Other, net

 

37

 

 

 

41

 

Other income (expense), net

 

644

 

 

 

570

 

(Loss) earnings before income taxes

 

(804

)

 

 

1,794

 

Income taxes

 

6,086

 

 

 

8,456

 

Net (loss) earnings

 

(6,890

)

 

 

(6,662

)

Net (loss) earnings attributable to redeemable noncontrolling interest

 

(1,334

)

 

 

(140

)

Net (loss) earnings attributable to USANA

$

(5,556

)

 

$

(6,522

)

 

 

 

 

(Loss) earnings per common share attributable to USANA

 

 

 

Basic

$

(0.30

)

 

$

(0.36

)

Diluted

$

(0.30

)

 

$

(0.36

)

 

 

 

 

Weighted average common shares outstanding

 

 

 

Basic

 

18,498

 

 

 

18,293

 

Diluted

 

18,498

 

 

 

18,293

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)

 

 

As of
October 3,
2026

 

As of
January 3,
2026

ASSETS

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

178,915

 

$

158,380

Trade accounts receivable (net of allowance of $96 and $137, respectively)

 

5,026

 

 

4,285

Inventories

 

84,082

 

 

102,608

Prepaid expenses and other current assets

 

22,219

 

 

23,132

Total current assets

 

290,242

 

 

288,405

Property and equipment, net

 

94,598

 

 

94,383

Goodwill

 

109,262

 

 

137,962

Intangible assets, net

 

120,411

 

 

133,151

Deferred tax assets

 

29,786

 

 

27,209

Other assets*

 

64,171

 

 

61,805

Total assets

$

708,470

 

$

742,915

 

 

 

 

LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY

 

 

 

Current liabilities

 

 

 

Accounts payable

$

17,662

 

$

17,263

Line of credit

 

—

 

 

14,000

Other current liabilities

 

94,592

 

 

97,302

Total current liabilities

 

112,254

 

 

128,565

Deferred tax liabilities

 

4,858

 

 

4,892

Other long-term liabilities

 

21,263

 

 

23,186

 

 

 

 

Redeemable noncontrolling interest

 

43,333

 

 

53,168

 

 

 

 

Total stockholders' equity attributable to USANA

 

526,762

 

 

533,104

Total liabilities, redeemable noncontrolling interest, and stockholders' equity

$

708,470

 

$

742,915

*

Includes noncurrent inventories of $9,229 and $4,799 as of October 3, 2026 and January 3, 2026, respectively. Total inventories were $93,311 and $107,407 as of October 3, 2026 and January 3, 2026, respectively.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
SALES BY REGION
(in thousands)
(unaudited)

 

 

Quarter ended

 

 

 

 

 

 

 

 

 

October 3,
2026

 

September 27,
2025

 

Change
from
prior
year

 

Percent
change

 

Currency
impact on
sales

 

Percent
change
excluding
currency
impact

Core Nutritional:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asia Pacific

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Greater China

$

93,882

 

45.6

%

 

$

92,571

 

43.3

%

 

$

1,311

 

 

1.4

%

 

$

4,109

 

 

(3.0

%)

Southeast Asia Pacific

 

29,885

 

14.5

%

 

 

29,178

 

13.7

%

 

 

707

 

 

2.4

%

 

 

138

 

 

2.0

%

North Asia

 

14,221

 

6.9

%

 

 

17,690

 

8.3

%

 

 

(3,469

)

 

(19.6

%)

 

 

(246

)

 

(18.2

%)

Asia Pacific total

 

137,988

 

67.0

%

 

 

139,439

 

65.3

%

 

 

(1,451

)

 

(1.0

%)

 

 

4,001

 

 

(3.9

%)

Americas and Europe

 

32,709

 

15.9

%

 

 

36,780

 

17.2

%

 

 

(4,071

)

 

(11.1

%)

 

 

203

 

 

(11.6

%)

Core Nutritional total

 

170,697

 

82.9

%

 

 

176,219

 

82.5

%

 

 

(5,522

)

 

(3.1

%)

 

 

4,204

 

 

(5.5

%)

Hiya

 

31,545

 

15.3

%

 

 

30,846

 

14.4

%

 

 

699

 

 

2.3

%

 

 

—

 

 

2.3

%

Rise

 

3,643

 

1.8

%

 

 

6,605

 

3.1

%

 

 

(2,962

)

 

(44.8

%)

 

 

—

 

 

(44.8

%)

Consolidated total

$

205,885

 

100.0

%

 

$

213,670

 

100.0

%

 

$

(7,785

)

 

(3.6

%)

 

$

4,204

 

 

(5.6

%)

 USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CORE NUTRITIONAL ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION
(unaudited)

 

Core Nutritional Active Brand Partners by Region(1)

(unaudited)

 

 

As of
October 3, 2026

 

As of
September 27, 2025

Asia Pacific

 

 

 

 

 

 

 

 

Greater China

 

57,000

 

35.2

%

 

61,000

 

36.3

%

Southeast Asia Pacific

 

46,000

 

28.4

%

 

43,000

 

25.6

%

North Asia

 

23,000

 

14.2

%

 

27,000

 

16.1

%

Asia Pacific Total

 

126,000

 

77.8

%

 

131,000

 

78.0

%

 

 

 

 

 

 

 

 

 

Americas and Europe

 

36,000

 

22.2

%

 

37,000

 

22.0

%

 

 

162,000

 

100.0

%

 

168,000

 

100.0

%

Core Nutritional Active Preferred Customers by Region(2)

(unaudited)

 

 

As of
October 3, 2026

 

As of
September 27, 2025

Asia Pacific

 

 

 

 

 

 

 

 

Greater China

 

135,000

 

69.6

%

 

149,000

 

67.7

%

Southeast Asia Pacific

 

15,000

 

7.7

%

 

18,000

 

8.2

%

North Asia

 

7,000

 

3.6

%

 

10,000

 

4.6

%

Asia Pacific Total

 

157,000

 

80.9

%

 

177,000

 

80.5

%

 

 

 

 

 

 

 

 

 

Americas and Europe

 

37,000

 

19.1

%

 

43,000

 

19.5

%

 

 

194,000

 

100.0

%

 

220,000

 

100.0

%

 ____________________

(1)

Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.

(2)

Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
OPERATING RESULTS AS A PERCENTAGE OF NET SALES
(unaudited)

 

 

 

Quarter ended

 

 

October 3, 2026

 

September 27, 2025

 

 

Core
Nutritional

 

Hiya

 

Rise

 

Consolidated

 

Core
Nutritional

 

Hiya

 

Rise

 

Consolidated

Net sales

 

100.0

%

 

100.0

%

 

100.0

%

 

100.0

%

 

100.0

%

 

100.0

%

 

100.0

%

 

100.0

%

Cost of sales

 

19.9

%

 

33.9

%

 

110.4

%

 

23.7

%

 

18.8

%

 

35.6

%

 

70.2

%

 

22.8

%

Gross profit

 

80.1

%

 

66.1

%

 

(10.4

)%

 

76.3

%

 

81.2

%

 

64.4

%

 

29.8

%

 

77.2

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Brand Partner incentives

 

42.1

%

 

—

%

 

—

 

 

34.9

%

 

44.1

%

 

—

%

 

—

%

 

36.4

%

Selling, general and administrative

 

33.9

%

 

86.2

%

 

46.0

%

 

42.1

%

 

35.9

%

 

66.5

%

 

32.5

%

 

40.2

%

Total operating expenses

 

76.0

%

 

86.2

%

 

46.0

%

 

77.0

%

 

80.0

%

 

66.5

%

 

32.5

%

 

76.6

%

(Loss) earnings from operations

 

4.1

%

 

(20.1

)%

 

(56.4

)%

 

(0.7

)%

 

1.2

%

 

(2.1

)%

 

(2.7

)%

 

0.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of acquired intangible assets

 

—

%

 

14.1

%

 

1.6

%

 

2.2

%

 

0.1

%

 

14.5

%

 

3.2

%

 

2.2

%

 

Contacts:

Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7210
investor.relations@usanainc.com

Media contact:
Sarah Searle
(801) 954-7626
media@usanainc.com

Source: USANA Health Sciences, Inc.

© 2026 Canjex Publishing Ltd. All rights reserved.